Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Lymphoid Enhancing Factor 1 (Lef-1) Overexpression In Epithelial Ovarian, Fallopian Tube And Peritoneal Cancer And Associations With Clinical Factors, Aine Clements, David Engle, Dawne Shelton, Traci Neff, Soo Park, David Bender, Amina Ahmed, Koen De Geest, Anna Button, John Engelhardt, Michael Goodheart
Lymphoid Enhancing Factor 1 (Lef-1) Overexpression In Epithelial Ovarian, Fallopian Tube And Peritoneal Cancer And Associations With Clinical Factors, Aine Clements, David Engle, Dawne Shelton, Traci Neff, Soo Park, David Bender, Amina Ahmed, Koen De Geest, Anna Button, John Engelhardt, Michael Goodheart
David P Bender
Lef-1 mRNA levels were statistically elevated in cases of ovarian, fallopian tube or peritoneal cancer when compared to non-cancerous controls. Among cancer cases, levels of Lef-1 were statistically different between stage and histology. Lef-1 overexpression may be predictive of poor overall survival. These findings suggest that Lef-1 overexpression may contribute to ovarian, fallopian tube and peritoneal carcinogenesis, and that further investigation is warranted.
The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie
The Combination Of Paclitaxel And Gefitinib Inhibits Endometrial Cancer Cells By Inducing Mitotic Catastrophe: Proof Of Principle For Dual Therapy In Endometrial Cancer, Xiangbing Meng, Laura Laidler, Lina Albitar, Anna Holmes, Donghai Dai, Thomas Buekers, David Bender, Kimberly Leslie
David P Bender
Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.